IP Library › Granted Patent US 10,792,314
Granted Patent B2
US 10,792,314 · App. 16/027,684 · Granted Oct 6, 2020

Compositions and methods of treating cancer using

Inventors: Peter Sandy (Revere, MA); Jacqueline Papkoff (San Francisco, CA); Maria Sizova (Roslindale, MA); Brian Goodman (Jamaica Plain, MA); Humphrey Gardner (Marblehead, MA); Holly Ponichtera (Cambridge, MA); Hank Wu (Cambridge, MA); William Caffry (Cambridge, MA); Anupriya Dutta (Brookline, MA)
Assignee: Evelo Biosciences, Inc.
A61K35/745A61K9/0019A61K9/0053A61K35/17A61K45/06A61P35/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,792,314
App. No.
16/027,684
Granted
Oct 6, 2020
Kind
B2
Abstract

Provided herein are methods and compositions related to Bifidobacterium animalis ssp. lactis useful as therapeutic agents.

Claims (15)

1. A pharmaceutical composition formulated for oral administration comprising Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) and a pharmaceutically acceptable carrier within an enteric coating.

2. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition is formulated in an enteric coated capsule.

3. The pharmaceutical composition of claim 2 , wherein the pharmaceutical composition comprises at least 7.5×10 10 CFUs of Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097).

4. The pharmaceutical composition of claim 1 , wherein the enteric coating is a coating for duodenal release at a pH of about 5.5-6.2.

5. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises an enteric coated tablet.

6. The pharmaceutical composition of claim 5 , wherein the bacterial composition comprises at least 7.5×10 10 CFUs of Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097).

7. The pharmaceutical composition of claim 1 , wherein at least 90% of the bacteria in the pharmaceutical composition are Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097).

8. The pharmaceutical composition of claim 1 , wherein substantially all of the bacteria in the bacterial composition are Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097).

9. The pharmaceutical composition of claim 1 , wherein the pharmaceutical composition comprises at least 7.5×10 10 CFUs of Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097).

10. The pharmaceutical composition of claim 1 , wherein the Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) are live bacteria.

11. The pharmaceutical composition of claim 1 , wherein the Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) are freeze-dried.

12. A pharmaceutical composition comprising at least 7.5×10 10 CFU of live Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) and a pharmaceutically acceptable carrier, wherein substantially all of the bacteria in the pharmaceutical composition are Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097), wherein the pharmaceutical composition comprises an enteric coated tablet, and wherein the enteric coating is a coating for duodenal release at a pH of about 5.5-6.2.

13. The pharmaceutical composition of claim 12 , wherein the Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) are freeze-dried.

14. A pharmaceutical composition comprising at least 7.5×10 10 CFU of live Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) and a pharmaceutically acceptable carrier, wherein substantially all of the bacteria in the pharmaceutical composition are Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097), wherein the Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) are in a capsule, and wherein the pharmaceutical composition comprises an enteric coating for duodenal release at a pH of about 5.5-6.2.

15. The pharmaceutical composition of claim 14 , wherein the Bifidobacterium animalis ssp. Lactis Strain A (ATCC Deposit Number PTA-125097) are freeze-dried.

Assignments (2)
SECURITY INTEREST Recorded Jul 14, 2023
From: EVELO BIOSCIENCES, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 064274/0354 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 19, 2019
From: SANDY, PETER; PAPKOFF, JACQUELINE; SIZOVA, MARIA; GOODMAN, BRIAN; GARDNER, HUMPHREY; PONICHTERA, HOLLY; WU, HANK; CAFFRY, WILL; DUTTA, ANUPRIYA
To: EVELO BIOSCIENCES, INC.
Reel/Frame 049520/0477 →
Continuity (2)
Provisional Application 62528669 · Jul 5, 2017
Related Publication 20190192585A1 · Jun 27, 2019